|
1
|
Epidemiology of invasive candidiasis: a persistent public health problem.
|
Clin Microbiol Rev
|
2007
|
15.66
|
|
2
|
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
|
J Clin Microbiol
|
2010
|
2.89
|
|
3
|
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
|
J Clin Microbiol
|
2009
|
2.47
|
|
4
|
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
|
J Clin Microbiol
|
2005
|
2.32
|
|
5
|
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
|
J Clin Microbiol
|
2004
|
2.31
|
|
6
|
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
|
J Clin Microbiol
|
2005
|
2.18
|
|
7
|
Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
|
J Clin Microbiol
|
2006
|
2.00
|
|
8
|
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
|
J Clin Microbiol
|
2007
|
1.65
|
|
9
|
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
|
J Clin Microbiol
|
2005
|
1.61
|
|
10
|
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
|
J Clin Microbiol
|
2007
|
1.55
|
|
11
|
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
|
J Clin Microbiol
|
2008
|
1.51
|
|
12
|
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
|
J Clin Microbiol
|
2006
|
1.42
|
|
13
|
Unusual fungal and pseudofungal infections of humans.
|
J Clin Microbiol
|
2005
|
1.33
|
|
14
|
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
|
J Clin Microbiol
|
2007
|
1.26
|
|
15
|
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
|
J Clin Microbiol
|
2006
|
1.13
|
|
16
|
Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.
|
J Clin Microbiol
|
2008
|
1.05
|
|
17
|
Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
|
J Clin Microbiol
|
2002
|
1.02
|
|
18
|
Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
|
J Clin Microbiol
|
2011
|
1.00
|
|
19
|
Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
|
J Clin Microbiol
|
2011
|
0.95
|